Hypidone hydrochloride - Shanghai Synergy Pharmaceutical Sciences
Latest Information Update: 26 Jul 2022
At a glance
- Originator Shanghai Synergy Pharmaceutical Sciences
- Class Antidepressants; Piperidines; Pyridines
- Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 26 Jul 2022 No development reported - Phase-II for Major depressive disorder in China (PO)
- 15 Jan 2021 Zhejiang Huahai Pharmaceutical completes a phase I trial for Major depressive disorder (In volunteers) in China (NCT04598607)
- 22 Oct 2020 Shanghai Synergy Pharmaceutical Sciences plans a phase I trial in Major depressive disorder (In volunteers) in China in October 2020 (PO, Tablet) (NCT04598607)